Boehringer Ingelheim

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval
Categories

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
Do you like it?
Read more
May 23, 2017
Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon
Categories

Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon

[vc_row][vc_column][vc_column_text] Dutch Contract Development & Manufacturing Organisation Patheon has been acquired by Thermo Fisher Scientific in a $7.2B deal. The acquisition, which includes the assumption of […]
Do you like it?
Read more